[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"systolic-heart-failure\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:systolic-heart-failure":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,68],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100643802","heart-failure-and-postoperative-outcome-in-surgery---a-national-registry-study-100643802",false,"NCT07634822","Heart Failure and Postoperative Outcome in Surgery - a National Registry Study","Incidence of Heart Failure and Its Association With Postoperative Mortality in Surgery - a National Registry Study","Inclusion Criteria:\n\n* ≥18 years of age who underwent surgery in Sweden between 1 Jan 2021-31 Dec 2024 and SPOR registered operation.\n\nExclusion Criteria:\n\n* ASA 6 (deceased patient, organ donation).\n* Cardiac surgery","ALL","18 Years",{"count":19,"type":20},2200000,"ESTIMATED","1 Year","OBSERVATIONAL","The study is an exploratory study that aims to explore the incidence of heart failure in a national surgical cohort, and to compare postoperative mortality and morbidity in patients with and without heart failure. Furthermore, we want to investigate differences in the incidence of heart failure and its impact on postoperative morbidity and mortality in day surgery compared to inpatient surgery.",[25,26,27],"Heart Failure","Diastolic Heart Failure","Systolic Heart Failure","NOT_YET_RECRUITING","2026-06-02",{"date":31,"type":32},"2026-06-09","ACTUAL",{"date":34,"type":20},"2026-08",{"date":36,"type":20},"2030-12",{"name":38,"class":39},"Umeå University","OTHER",2,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":67},"100567655","a-trial-comparing-high-flow-nasal-cannula-versus-noninvasive-ventilation-on-reintubation-and-post-extubation-respiratory-failure-in-high-risk-patients-with-systolic-heart-failure-100567655","NCT06671015","A Trial Comparing High-Flow Nasal Cannula Versus Noninvasive Ventilation on Reintubation and Post-Extubation Respiratory Failure in High-Risk Patients With Systolic Heart Failure","A Prospective Randomized Controlled Trial Comparing High-Flow Nasal Cannula Versus Noninvasive Ventilation on Reintubation and Post-Extubation Respiratory Failure in High-Risk Patients With Systolic Heart Failure","EXTUBATE-HF","Inclusion Criteria:\n\n* The patient is a male or non-pregnant female greater than or equal to 18 years of age\n* The patient is ventilated for greater than 24 hours\n* The patient has a systolic left ventricular dysfunction defined as an ejection fraction less than or equal to 40%\n* The patient, or legally authorized representative, has been informed of the nature of the study, agrees to its provisions, and has provided written informed consent, approved by the appropriate Institutional Review Board (IRB) or Ethics Committee (EC).\n\nExclusion Criteria:\n\n* Patients actively being treated for a COPD exacerbation or known hypercapnia (PaCO2\\>45) on last Arterial Blood Gas (ABG)\n* Patients agitated or uncooperative state\n* Patients with do-not-resuscitate orders\n* Patients presenting with tracheostomies or anatomical abnormalities interfering with mask fit\n* Patients are prisoners\n* Patient self-extubates\n* Patients with pre-existing NIV prescription (e.g., obstructive sleep apnea, neuromuscular disorders, advanced COPD)",{"count":50,"type":20},50,"INTERVENTIONAL",[53],"NA","This prospective, open-label randomized controlled pilot trial will enroll participants at the Yale New Haven Hospital. Patients with systolic heart failure, defined as an ejection fraction ≤40%, who require invasive mechanical ventilation (IMV) and are admitted to either the cardiac intensive care unit (CICU) or medical ICU (MICU) will be included.\n\nSubjects meeting eligibility criteria will be randomized 1:1 to one of the two treatment groups:\n\n* Intervention: Extubation to high-flow nasal cannula (HFNC)\n* Control: Extubation to non-invasive ventilation (NIV)",[27,56],"Respiratory Failure","RECRUITING","2026-05-26",{"date":60,"type":32},"2026-05-28",{"date":62,"type":32},"2025-10-04",{"date":64,"type":20},"2027-02",{"name":66,"class":39},"Yale University",1,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":51,"phases":78,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":67},"100456987","neuromodulation-of-inflammation-and-endothelial-function-100456987","NCT05230732","Neuromodulation of Inflammation and Endothelial Function","Neuromodulation of Inflammation and Endothelial Function to Treat Elderly Patients With Systolic Heart Failure","Inclusion Criteria:\n\nSystolic heart failure with EF \\\u003C or equal to 50%.\n\nExclusion Criteria:\n\n1. patients in overt congestive heart failure \u002F recent acute myocardial infarction (\\\u003C 4 weeks) or Unstable angina\n2. Active malignancy\n3. unilateral or bilateral vagotomy\n4. pregnant patients\n5. End stage liver disease\n6. history of recurrent vasovagal syncope, Sick sinus syndrome with no pacemaker, 2nd or 3rd degree AV block.\n7. Significant hypotension (Blood pressure \\\u003C 90 mm Hg) secondary to autonomic dysfunction","85 Years",{"count":77,"type":20},158,[53],"Heart failure with reduced ejection fraction (HFrEF) is a major cause of mortality in United States. Aging is a major risk factor for adverse outcomes associated with HFrEF, with majority of the patient's over the age of 50, continuing to experience symptoms, reduced exercise capacity and poor quality of life. We have previously demonstrated that low level transcutaneous electrical stimulation of the vagus nerve at the tragus (LLTS) suppresses inflammation in patients with atrial fibrillation and diastolic dysfunction and improved endothelial dysfunction in patients with chronic heart failure. The overall objective of this proposal is to examine the effects of LLTS on heart failure symptoms, exercise capacity and quality of life in patients with HFrEF and simultaneously determine the impact of LLTS on the suppression of inflammation and improvement in endothelial function. Our specific aims include: 1. To examine the medium term effect of intermittent (1 hour daily for 3 months) LLTS on exercise capacity and quality of life, related to sham stimulation, in patients with HFrEF, 2. To determine the effects of medium-term LLTS on sympathovagal\u002Fautonomic balance (assessed by heart rate variability) and systemic inflammation in patients with HFrEF and 3. To determine the effects of medium-term LLTS on endothelial function in patients with HFrEF. The proposed proof-of-concept human studies will provide the basis for the design of further human studies using LLTS among larger populations with HFrEF. In light of the increasing number of elderly patients who continue to experience HFrEF symptoms, recognized is a key point of interest in this funding mechanism, and the suboptimal success of the currently available treatment options to ameliorate the problems mentioned above, an alternative novel approach such as LLTS has the potential to impact clinical practice and improve health outcomes among the large number of patients. It is anticipated that these investigations will contribute to a broader understanding of the role of autonomic imbalance, inflammation and endothelial dysfunction in the pathogenesis of HFrEF and how its inhibition can be used to provide therapeutic effects. Moreover, it is anticipated that a better understanding of how modulation of autonomic tone, inflammation and endothelial function affects one of the hallmarks of HFrEF will lead to the development of normal nonpharmacological and pharmacological approaches to treat this disease.",[27],"2025-04-10",{"date":83,"type":32},"2025-04-15",{"date":85,"type":32},"2022-09-01",{"date":87,"type":20},"2026-02-27",{"name":89,"class":39},"University of Oklahoma"]